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Kidney transplant nephrotic syndrome: Relationship between
allograft histopathology and natural course. We analyzed clinical
and pathologic data from 36 recipients of 38 renal allografts who
developed nephrotic syndrome following transplantation. Three
groups were identified on the basis of histologic changes in the
graft, and each group had a distinct clinical course. Nine grafts
(23.7%) had recurrent glomerulonephritis (GN) (5 membrano-
proliferative, 4 focal glomerulosclerosis) and developed nephrot-
ic syndrome at 5.1 months (mean) posttransplant. Renal function
deteriorated rapidly, with a 2-year graft survival of 29.7%. Four
grafts (10.5%) with de novo GN (3 epimembranous, 1 minimal
change) developed nephrotic syndrome at 32 months post-
transplant, and all functioned for more than 3 years. Twenty-five
grafts (65.8%) had allograft glomerulopathy with the onset of
nephrotic syndrome at 9.1 months posttranspiant and a 2-year
graft survival of 66.6%. The differences in duration of graft func-
tion between grafts with allograft glomerulopathy and recurrent
GN (P < 0.01) and in graft survival rates at 2 years among the
three groups (P <0.05) are statistically significant. This analysis
indicates that allograft glomerulopathy is the most common
cause of kidney transplant nephrotic syndrome. Membranopro-
liferative GN and focal glomerulosclerosis may recur soon after
transplantation and rapidly progress to renal failure in marked
contrast to grafts with either de novo epimembranous nephropa-
thy or minimal glomerular change, lesions that are compatible
with prolonged graft function.
Syndrome néphrotique du rein transpianté: Relations entre
l'histopathologies de l'allogreffe et l'évolution. Nous avons ana-
lysé les dossiers cliniques et anatomo-pathologiques de 36 rece-
veurs de 38 allogreffes qui ont développé un syndrome néphro-
tique après transplantation. Trois groupes ont été identifies sur
Ia base des modifications histologiques de Ia greffe et chaque
groupe a eu une evolution distincte. Neufgreffes (23,7%) ont eu
une récidive de glomérulonéphrite (GN) (5 membrano-pro-
lifératives, 4 gloméruloscléroses focales) et ont développé un
syndrome néphrotique 5,1 mois (moyenne) après Ia trans-
plantation. La fonction rCnale s'est détériorée rapidement, avec
une survie de Ia greffe a 2 ans de 29,7%. Quatre greffes (10,5%)
atteintes de GN nouvelle (3 extra-membraneuses, 1 a modifica-
tions minimes) ont développé un syndrome néphrotique 32 mois
après Ia transplantation et ont toutes fonctionné plus de 3
ans. Vingt cinq greffes (65,8%) ont eu une glomdrulopathie de
greffe avec l'installation d'un syndrome néphrotique 1 9,1 mois
après Ia transplantation et une survie de la greffe a 2 ans de
66,6%. Les differences de durée du fonctionnement de la greffe
scion i'atteinte par une récidive de UN ou une glomérulopathie
de greffe (P <0,01) et dans Ia survie des greffes a 2 ans dans les
trois groupes (P <0,05) sont statistiquement significatives. Cette
analyse indique que Ia glomérulonéphrite de la greffe est Ia cause
Ia plus répandue de syndrome néphrotique du rein transpianté.
La UN membrano-proliférative et Ia glomérulosclérose focale
peuvent récidiver précocément après Ia transplantation et prog-
resser rapidement vers l'insuffisance rénale a Ia difference des
greffes atteintes de néphropathie extramembraneuse ou de modi-
fications minimes, lesions compatibles avec une fonction pro-
longée de Ia greffe.
Proteinuria and nephrotic syndrome frequently
occur in recipients of kidney transplants. Protein-
uria in the immediate postoperative period com-
monly recedes, and neither its amount nor duration
has any prognostic significance [1, 2]. Some trans-
plant recipients, however, continue to have or sub-
sequently develop heavy and persistent proteinuria
during later stages of their posttransplant course.
The incidence of established nephrotic syndrome in
recipients of renal allografts [3, 4] or isografts [5]
approaches 30%. The causes of transplant nephrot-
ic syndrome have been attributed to allograft
glomerulopathy' [3, 4], recurrent or de novo gb-
merulonephritis (GN) [5—9], renal vein thrombosis
[10, 11], and reflux nephropathy [12]. Although kid-
ney transplant nephrotic syndrome has been the
subject of intensive clinical investigation, few at-
tempts have been made to correlate its natural
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I The term 'allograft glomerulopathy" is used here to de-
scribe nonspecific histopathologic changes in renal allografts of
unknown etiology, but presumably due to chronic aliograft rejec-
tion.
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course with histopathologic alterations in the allo-
grafts and in the original kidney disease. To deter-
mine the natural course of kidney transplant ne-
phrotic syndrome and its relation to underlying
pathologic processes, we analyzed clinical and
pathologic data from 38 renal allografts in 36 pa-
tients with posttransplant nephrotic syndrome.
Methods
Patient population. From May 1963, to Decem-
ber 1976, 599 renal transplants were performed in
520 patients at The New York Hospital-Cornell
University Medical Center. Among the 599 renal al-
lografts, 54 instances of nephrotic syndrome (de-
fined as urinary protein excretion of  3.0 g/day and
persisting for at least 6 months) developed in 52 re-
cipients. Tissue specimens of the recipients' native
kidneys and allografts were available for pathologic
studies from 36 of the patients, involving 38 allo-
grafts. These 36 transplant recipients are the sub-
jects of this study.
The patients' ages at the time of transplantation
ranged from 8 to 54 years (24 [SEMI 5); 24 were
males and 12 were females. Twenty-six kidney
transplants were from living related donors and 12
from cadaveric donors. None of the patients re-
ceived kidneys from an identical twin, but two re-
ceived kidneys from fraternal twins. Two patients
developed nephrotic syndrome in two consecutive
transplants. Both received first kidneys from living
related donors, and second kidneys from cadaveric
donors.
Standard surgical procedures including Paquin
technique of ureteroneocystostomy [13] were used.
All patients received standard regimens of immuno-
suppressive agents consisting of azathioprine and
prednisone beginning on the day before or on the
day they received the transplant. At the time of
transplant, all patients were given 3 to 5 mg/kg/day
of azathioprine and 100 to 200 mg/day of predni-
sone. Doses of both agents were gradually reduced
to 2 mg/kg/day of azathioprine and 5 to 20 mg/day of
prednisone. The prednisone dose was increased
transiently during episodes of acute transplant re-
jection to as high as 1,000 mg/day and reduced to
maintenance levels within a few weeks. The aver-
age daily maintenance dose was 95 mg of azathio-
prine and 16 mg of prednisone. No patients in this
series received antithymocyte globulin.
All patients were followed by the physicians of
the kidney center at different time intervals depend-
ing on the stability of graft function and patient stat-
us. Followup period for the functioning allografts
was at least 10 months, and the longest was more
than 15 years (38 [SEMi 5.5 months). Graft surviv-
al is defined as graft function sufficient to sustain
health without chronic dialysis. Actuarial survival
rates for the grafts were calculated by the life table
method.
Pathologic studies. The tissue specimens ob-
tained by either biopsy or nephrectomy were fixed
in Bouin's solution, and serial sections 2 to 4 p thick
were stained for light microscopy with hematoxylin
and eosin, periodic acid-Schiff, Azan, reticulin
stain, and phosphotungstic acid hematoxylin stain.
Tissue for immunohistochemical study was pro-
cessed by standard techniques and stained with flu-
oresceinated antisera to IgG, IgA, 1gM, C3, and fi-
brinogen. Tissue for electron microscopic examina-
tion was processed by standard techniques and
embedded in Epon epoxy resin. Representative
areas were stained with uranyl acetate and lead cit-
rate, and examined with an RCA electron micro-
scope.
Slides were studied independently by two pathol-
ogists (J.M. and M.S.) without knowledge of the
clinical history or of the original renal disease. The
only information available was that these were from
renal transplants associated with the nephrotic syn-
drome.
Histologic characteristics of chronic allograft re-
jection were determined by review of material from
12 cadaveric allografts (in recipients whose original
kidney diseases were of nonglomerular origins) that
functioned between 10 months and 4 years with epi-
sodes of clinical allograft rejection, but without pro-
teinuria, and from the information available from
literature (5—7, 14—18). Criteria we arrived at for de-
termination of allograft glomerulopathy, recurrent
GN, or de novo GN were:
(I) Allograft glomerulopathy. The glomerular
changes of allograft glomerulopathy are generally
mild and variable. The vascular and interstitial
changes are severe or disproportionately more ad-
vanced than are the glomerular changes. Findings in
the glomeruli by light microscopy include thick-
ening and wrinkling of the capillary basement mem-
branes, increase in mesangial matrix with slight and
variable cellular proliferation and contraction of the
tufts with solidification and sclerosis. Occasionally,
splitting or double contour patterns of the glorneru-
tar capillary walls is observed, but these alterations
are not associated with appreciable hypercetlularity
or hyperlobulation. Vascular changes include endo-
thelial cell swelling and proliferation with onion-
skin change of intima resulting in an obliterative ar-
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teriopathy. Interstitial changes are associted with fi-
brosis, mononuclear cellular infiltrates, and varying
degrees of tubular atrophy. By electron micros-
copy, predominantly subendothelial electron-lucent
deposits are seen together with 1gM deposits by im-
munofluorescence techniques.
(2) Glomerulonephritis. A diagnosis of recurrent
GN was made only when the morphologic pattern in
the allografts studied by light microscopic, electron
microscopic, and immunohistochemical techniques
was similar to that which caused renal failure in the
native kidneys. Glomerular changes attributed to
recurrent GN were characterized by their severity
in contrast to the accompanying interstitial and vas-
cular changes, which tended to be minimal or dis-
proportionately milder than were the glomerular
changes. Because focal segmental sclerotic changes
due to allograft rejection tend to preferentially in-
volve outer cortical glomeruli (unpublished data) as
opposed to juxtamedullary glomeruli as seen in
idiopathic focal glomerulosclerosis, we also studied
the distribution of the involved glomeruli to aid in
differential diagnosis. If the predominant histologic
pattern that affected the glomeruli did not resemble
those seen in the native kidney, or if the original
disease was nonglomerular, then a diagnosis of de
novo GN was made.
Approximately two thirds of these specimens
were studied by electron microscopy and immuno-
histochemical techniques. Pertinent information
from these morphologic techniques, together with
correlations with the clinical course (Fig. 1), was
important in the classification of the allograft pa-
thology.
Results
Causes of original kidney diseases. Twenty-eight
patients had glomerular diseases whereas 8 had
nonglomerular diseases, such as polycystic kidney
disease, obstructive uropathy, medullary cystic dis-
ease, and tubulointerstitial nephritis (Table 1). Of
the 28 patients with glomerular disease, 7 had focal
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Table 1. Histopathology of native kidneys and allograftsa
Allograft
glomerulopathy
Recurrent
GN
De novo
GN
Glomerular diseases (N = 28)
FGS(N=7)' 5 4
TypeIMPGN(N=5) 5
Epimembranous GN
(N=5) 5
Proliferative GN
(N=5) 3 2
Unclassifiable (N = 6) 4 2
Nonglomerular dis-
eases (N = 8) 8
Total (N = 36) 25(65.8%) 9(23.7%) 4(10.5%)
Figures denote number of cases. Abbreviations used are:
GN, glomerulonephritis; FGS, focal glomerulosclerosis; MPGN,
membranoproliferative GN.
Two of these patients developed nephrotic syndrome in two
consecutive transplants.
Although MPGN was a predominant finding in the allografts,
3 of these also had histopathologic changes consistent with allo-
graft glomerulopathy.
glomeruloscierosis (FGS), 5 type I membranopro-
lilerative GN (MPGN), 5 epimembranous nephropa-
thy, 5 proliferative GN, and 6 had unclassifiable gb-
merular diseases due to either atypical glomerular
abnormalities or too advanced glomerular changes.
There was no patient with either anti-GBM anti-
body nephritis or type II MPGN (dense-deposit dis-
ease).
Histopathologic findings in allografts. Three ma-
jor groups of histopathologic abnormalities were
identified from the 38 renal allografts. These were
allograft glomerulopathy, recurrent GN, and de
novo GN (Table 1).
Of 9 allografts transplanted into the 7 patients
with FGS, 4 had recurrence of FGS. Two patients
with FGS, the only pediatric patients in this series,
developed nephrotic syndrome in two consecutive
transplants. One had a recurrence of FGS in both
allografts whereas the other had chronic rejection
only in the first allograft, with a recurrence of FGS
in the second.
Of the 5 patients with type I MPGN, all devel-
oped a recurrence of the same disease in the allo-
graft. Of these, however, 3 also had histologic
changes consistent with allograft glomerulopathy.
Three of the patients had normal serum com-
plement levels, and two had persistent hypocomple-
mentemia during the course of their original kidney
disease, dialysis treatment, after transplantation,
and after transplant nephrectomy.
Although all 5 of our patients with MPGN were
classified as recurrent GN, it is frequently difficult
in a specific case to be certain that the lesion repre-
sents a true recurrence rather than a manifestation
of allograft glomerulopathy [16]. This was espe-
cially true in 3 of the 5 patients in whom the MPGN
was associated with allograft glomerulopathy.
Based, however, on findings of similarities with the
native kidney lesions and electron microscopic
study, as well as serum complement determina-
tions, we concluded that the findings were most
compatible with recurrence of MPGN.
All allografts in patients with epimembranous ne-
phropathy revealed allograft glomerulopathy, and
none had a recurrence of the original disease.
Of the 5 albografts in patients with proliferative
glomerulonephritis, 3 demonstrated albograft gb-
merulopathy, but 2 developed de novo epimembra-
nous nephropathy with subepithelial deposits. None,
however, had a recurrence of the original disease.
Of the 6 allografts in patients whose original dis-
eases were glomerulonephritides that could not be
classified, 4 had allograft glomerulopathy only, 1
epimembranous nephropathy with typical sub-
epithelial electron-dense deposits, and 1 minimal
change in two open biopsies while the patient was
nephrotic. Although we could not be certain of the
exact nature of the original glomerular lesions in the
latter 2 patients, neither the clinical data nor the
pathologic findings were supportive of the diagnosis
of epimembranous nephropathy or minimal change
disease. Thus, the gbomerulopathies found in them
represent de novo GN.
All 8 patients with nonglomerular disease re-
vealed only allograft gbomerulopathy in their grafts.
None of the patients had vesicoureteral reflux or
renal vein thrombosis in the transplanted kidney
when these were evaluated by radiographic or path-
ologic studies (13 nephrectomized specimens and 10
postmortem examinations).
Thus, the histopathologic alterations found in 38
renal albografts from 36 patients with the nephrotic
syndrome were attributable to allograft glomerulop-
athy in 25 (65.8%), recurrent GN in 9 (23.7%), 3 of
which also had coexisting albograft gbomerulopathy,
and de novo GN in 4 (10.5%).
Clinical course. The clinical course of individual
patients in relation to nephrotic period, episodes of
acute rejection, and the ultimate fate of allografts or
patients is depicted in Fig. 1. The mean values of
the time of onset of nephrotic syndrome from the
date of transplantation, the duration of graft func-
tion, and actuarial graft survival rates in each group
are presented in Table 2. The actuarial graft surviv-
al rates are also graphically depicted in Fig. 2. Be-
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Table 2. Clinical course of allograftsa
Allograft Recurrent De novo
glomerulopathy GN GN Statistical(N = 25) (N = 9) (N = 4) significance
Onset of nephrotic syndrome, months
Range
Mean SEM
I to 48
9.1 2.17
ito 22
5.1 2.26
2 to 74
31.5 15.37 N
Duration of graft function at
close of study, months
Range
Mean SEM
lOto 113
31.2 7.35
10to29
16.7 2.37
4Oto 180
92.3 25.17 P<OOl.
Actuarial graft survival, % by 2 yr 66.6 29.7 100 P < 0.05
a N denotes number of allografts. GN is glomerulonephritis.
cause the number of patients with MPGN or FGS
are small, and their clinical courses are similar,
these patients are combined into one group in Table
2 and Fig. 2.
The allografts with recurrent GN (4 with FGS and
5 with type I MPGN) became nephrotic earlier, usu-
ally within 6 months of transplant. The clinical
course of the disease was rapidly progressive and
the duration of graft function was significantly
shorter than that of the other allografts. The pro-
gression of their original kidney disease from clini-
cal onset to renal failure varied from 6 months to 13
years (54.4 [SEMI 7.5 months). Of these 9 patients
with recurrent GN, however, 8 became nephrotic
within 7 months and all allografts ceased function-
ing within 3 years after transplantation, irrespective
of the duration of their original disease. Thus, there
is no correlation between the duration of the origi-
nal kidney disease and the time of progression to
renal failure following transplantation.
In contrast, those allografts with de novo GN be-
came nephrotic 2 to 3 years after transplantation,
although one allograft with minimal glomerular
change developed nephrotic syndrome 2 months af-
ter transplantation. Furthermore, all allografts with
de novo GN functioned for at least 3 years, and one
even continues to function for more than 15 years.
In grafts with allograft glomerulopathy alone, the
time of onset of nephrotic syndrome and duration of
graft function were intermediate between those of
allografts with recurrent GN and de novo GN.
When the duration of kidney function is esti-
mated by the product-limit method of Kaplan and
Meier [19], the patients with allograft glomerulop-
athy have a significantly longer (P <0.01) duration
of kidney function than do patients with recurrent
GN. There are, however, too few patients with de
novo GN to permit a valid comparison with the oth-
er groups. The differences in actuarial survival rates
for the grafts at 2 years among the three groups
were statistically significant (P < 0.05) by the x2
test.
Discussion
Histopathologic abnormalities in long-term renal
allografts have been extensively studied, and histo-
logic similarities between lesions caused by recur-
rence of original GN and by allograft glomerulopa-
thy, as well as difficulties in differentiating between
their lesions, have been emphasized [6, 7, 9, 16, 17,
20—23]. Few studies, however, are available that
correlate the course of allografts with different un-
derlying pathologic processes, such as allograft
glomerulopathy, recurrent GN, and de novo GN.
Although the histopathologic criteria we used in
this study to differentiate allograft glomerulopathy
from glomerulonephritis are not absolute, their va-
lidity is supported by other studies. Glassock et al
55
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Fig. 2. Actuarial graft survival of allografts. Figures denote num-
ber of patients at risk during each observation period. N denotes
total number of patients at risk at the beginning of the study.
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[5] reported 11 cases of recurrent GN in 22 renal
isograft recipients. These isografts serve as a proto-
type of recurrent GN in grafts without additional al-
terations due to transplant rejection. The pre-
dominant histopathologic features of recurrent GN
in these isografts were in the glomeruli. Arterial and
interstitial abnormalities were minimal, even
though the degree of GN was severe enough to lead
to renal failure in 5 patients.
As a control for our study, we reviewed patholog-
ic material from 12 cadaveric allografts that func-
tioned between 10 months and 4 years in patients
whose original kidney diseases were non-
glomerular. Abnormalities in these allografts are
characteristic of allograft glomerulopathy presum-
ably mediated by sensitization to histocompatibility
antigens expressed in the grafts with little likelihood
of GN. The predominant and characteristic abnor-
malities in these allografts were obliterative arteri-
opathy and tubulointerstitial changes with only mild
and variable glomerular abnormalities. These find-
ings are consistent with histopathologic findings in
chronic allograft rejection described in other studies
as reviewed by Rowlands, Hill, and Zmijewski [14],
Corson [15] and Cameron and Turner [17].
Chronic kidney transplant nephrotic syndrome
has been attributed primarily to allograft glomeru-
lopathy [3, 4], recurrent or de novo GN [5, 9], renal
vein thrombosis [10, 11], and reflux nephropathy
[12]. Our analysis reveals that allograft glomerulop-
athy is the single most common cause of nephrotic
syndrome, regardless of the nature of recipients'
original kidney disease, comprising 65.8% of total
renal allografts. Recurrent and de novo GN are less
common but not infrequent causes of the nephrotic
syndrome comprising 23.7% and 10.5%, respective-
ly. Thus, although other causes might be respon-
sible for transplant nephrotic syndrome in unusual
instances, allograft glomerulopathy and recurrent
or de novo GN are the major processes responsible
for nephrotic syndrome. This observation is consis-
tent with previous reports indicating that allograft
glomerulopathy is the most common cause for
nephrotic syndrome in allograft recipients, whereas
recurrent glomerulonephritis is the most common
cause for that in isograft recipients [3—6].
Our results should not be interpreted as in-
dicating the relative incidence of recurrent or de
novo GN in transplant recipients, because we ana-
lyzed only those patients who became nephrotic.
Our findings do indicate, however, that recurrence
of GN (particularly MPGN and FGS) and de novo
GN do occur and cause nephrotic syndrome in sub-
stantial numbers of renal allografts that function for
prolonged periods.
Each group of patients has a distinct clinical
course. The patients with recurrent GN develop
nephrotic syndrome in the early posttransplant peri-
od and rapidly progress to renal failure, as com-
pared with those patients with de novo epimem-
branous nephropathy, in whom nephrotic syndrome
develops later in the posttransplant period and the
clinical course is slow and indolent. Patients with
allograft glomerulopathy alone, however, follow a
course that is intermediate between these two ex-
tremes. Thus, biopsy studies of allografts from
nephrotic patients help to clarify the underlying
process causing the nephrotic syndrome, and help
to estimate the prognosis of the graft.
The reported incidence of recurrent glomerulone-
phritis in renal allografts ranges from 5 to 18% [5—7,
9, 17, 20, 21], and the clinical course of such pa-
tients is generally reported to be shorter and more
rapidly progressive to renal failure than that of the
original kidney disease [5, 23]. Our results are con-
sistent with this experience and indicate that recur-
rence of MPGN and FGS begins early, usually with-
in 6 months, with the onset of nephrotic syndrome.
The renal lesion progresses rapidly to renal failure
within 3 years after transplantation, regardless of
the duration of the original disease or the duration
of dialysis treatment prior to the transplantation.
Reasons for the differences in the clinical course
of original versus recurrent glomerulonephritis are
not immediately evident. Anatomical (size of renal
mass) and functional (number of nephron units) fac-
tors may play a role. Other factors, however, may
be more important, such as the presence of several
pathologic processes (allograft glomerulopathy and
recurrent glomerulonephritis) and, possibly, the
more frequent exposure of the graft to nephrotoxic
antibiotics and radiographic contrast agents. The
presence of allograft glomerulopathy in addition to
recurrent glomerulonephritis, as seen in 3 of 5 allo-
grafts with MPGN in this study as well as 3 of 14
allografts with MPGN reported by Berthoux et al
[24], might be more detrimental to allograft survival
than recurrent glomerulonephritis alone. Beyer et a!
[25] reported that histologic changes of glomerulo-
nephritis are more severe and rapidly progressive in
unilaterally nephrectomized animals than they are
in sham-operated animals. The authors speculated
that the accelerated course of glomerulonephritis
after unilateral nephrectomy is due to a higher den-
sity of immune complexes to each remaining neph-
ron as the number of circulating complexes is held
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constant but the number of glomeruli is reduced by
unilateral nephrectomy, and that glomerular dam-
age is proportional to the concentration of immune
complexes impinging on each glomerulus. A similar
mechanism could play a role in the accelerated
course of recurrent GN in renal allografts.
The presence of nephrotic syndrome in patients
with idiopathic MPGN [26] or FGS [27], as well as
in transplant recipients [28], has been associated
with a poor prognosis. Because this study includes
only patients who have had nephrotic syndrome,
the clinical course of our patients with recurrent
glomerulonephritis may be biased towards a poorer
prognosis than it is for patients with recurrent gb-
merulonephritis without nephrotic syndrome [17].
A patient with recurrent FGS reported by Cameron
and Turner, was healthy, however, with good graft
function for over 3 years, despite persisting ne-
phrotic syndrome.
Development of de novo [29] as well as recur-
rence of epimembranous nephropathy [30, 31] has
been observed previously, and various viral agents
have been suggested as antigenic stimulants for im-
mune complex formation. In this study, there were
3 allografts with epimembranous nephropathy in pa-
tients whose original kidney disease was probably
not of the same nature. One of these had had chron-
ic hepatitis B surface antigenemia prior to onset of
nephrotic syndrome. It is difficult to be certain
whether the cases classified as de novo epimem-
branous nephropathy belong to true de novo gb-
merulopathies or are related to some other patho-
logic process. The epimembranous nephropathy in
renal allografts could be a renal response to the
original nephritogenic stimuli or an example of im-
mune complex nephropathy due to the interaction
of alloantigen and alloantibody, thereby represent-
ing a form of either recurrent glomerulonephritis or
allograft glomerulopathy. Regardless of the precise
mechanism responsible for this pattern, the clinical
course of allografts with this pattern is strikingly
indolent and benign, in sharp contrast to those
allografts with recurrent glomerulonephritis. Ap-
parently, the lesion develops some time later in
the posttransplant period (2 to 3 years after
transplantation), and the allografts maintain stable
function for many years thereafter. This observa-
tion is consistent with other reports of de novo or
recurrent epimembranous nephropathy and is re-
markably similar to the natural course of idiopathic
epimembranous nephropathy [32]. The benign and
indolent course of allografts with epimembranous
nephropathy might be due at least in part to immu-
nosuppressive therapy, because such therapy has
recently been shown to be helpful in idiopathic epi-
membranous nephropathy [33, 34].
Allografts with minimal changes have been ob-
served previously and characterized by severe pro-
teinuria and nephrotic syndrome starting within 1 to
2 months after transplantation [8, 9, 35]. Although 3
of these were proven to be cases of FGS in sub-
sequent studies and progressed to renal failure [8],
one of them remitted 2 years after transplantation
[35]. One of our patients, a recipient of a fraternal
twin's kidney, became nephrotic 2 months after
renal transplantation. Two kidney biopsies per-
formed while she was nephrotic showed only mini-
mal glomerular changes. Despite severe and pro-
longed nephrotic syndrome, she has maintained a
well-functioning albograft for over 15 years and gave
birth to three normal children during this period.
Furthermore, she is the only patient in this series in
whom proteinuria resolved and who has maintained
excellent graft function after a protracted course of
nephrotic syndrome.
Allograft glomerulopathy is the most common
cause for transplant nephrotic syndrome, and its
clinical course is insidious and slowly progressive.
As shown in our previous studies [4, 28], the pres-
ence of nephrotic syndrome in renal allograft recipi-
ents, particularly related donor kidney recipients, is
a factor that adversely affects, albeit to a mild ex-
tent, their natural courses. Among the nephrotic pa-
tients, however, the survival rate of grafts with allo-
graft gbomerubopathy is significantly better than that
of grafts with recurrent glomerulonephritis. A simi-
lar result has been reported previously by Ham-
burger et al [22] and Starzl et al [36], who have
shown that grafts with histologic changes consistent
with allograft glomerulopathy tend to have a more
favorable prognosis than those with recurrent
gbomerulonephritides. The grafts with allograft
glomerulopathy, however, do ultimately progress to
renal failure, and about half cease functioning by 3
years after transplantation.
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